OmniAb, Inc. (OABI)
(Delayed Data from NSDQ)
$1.95 USD
+0.04 (2.09%)
Updated Aug 4, 2025 04:00 PM ET
After-Market: $1.96 +0.01 (0.51%) 5:36 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
OABI 1.95 +0.04(2.09%)
Will OABI be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for OABI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for OABI
OmniAb, Inc. (OABI) Reports Q1 Loss, Misses Revenue Estimates
OmniAb, Inc. (OABI) Reports Q4 Loss, Tops Revenue Estimates
OABI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Nektar Therapeutics (NKTR) Q4 Earnings Miss Estimates (Revised)
Nektar Therapeutics (NKTR) Q4 Earnings Beat Estimates
Verve Therapeutics (VERV) Reports Q4 Loss, Tops Revenue Estimates
Other News for OABI
OmniAb to Report Second Quarter 2025 Financial Results on August 6 | OABI Stock News
Analysts Offer Insights on Healthcare Companies: Galapagos (GLPG), OmniAb (OABI) and Bristol-Myers Squibb (BMY)
OmniAb Elects Directors at Annual Shareholder Meeting
AbCellera Biologics: The Dilemma Of A Promising Pipeline Alongside Cash Burn
Tourlite Capital Q1 2025 Investor Letter